Skip To Main Content
Phil Taylor on Muck Rack

Phil Taylor

Verified
Birmingham
As seen in: Pharmaphorum, Sports Illustrated, EIN News, Fierce Pharma, Fierce Biotech, Nuvo, PMLiVE, Securing Industry

Get in touch with Phil

Contact Phil, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Phil Taylor’s Biography

Read Full Bio →

Healthcare hack (cough)

Articles

Pfizer, Valneva Lyme vaccine starts review in Europe

|
By Phil Taylor Verified
| Pharmaphorum Verified
News After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU, and the EMA has started its review.
Open in Who Shared View Duplicates (2) Issue with article?

BMS bags first approval for myeloma CELMoD Zenbexus

|
By Phil Taylor Verified
| Pharmaphorum Verified
Bristol Myers Squibb's CELMoD pipeline has delivered its first regulatory approval, for iberdomide, as a combination therapy for patients with multiple myeloma. First-in-class iberdomide has been given accelerated approval under the Zenbexus brand name, alongside Johnson & Johnson and Genmab's Darzalex (daratumumab) and dexamethasone in a regimen known as ZDd, as a second-line or later therapy for the blood cancer.
Open in Who Shared Issue with article?

FDA cites 'significant concerns' with ADC lymphoma trial

|
By Phil Taylor Verified
| Pharmaphorum Verified
News ADC Therapeutics' chief executive, Ameet Mallik. ADC Therapeutics' chances of upgrading its accelerated approval for diffuse large B-cell lymphoma therapy Zynlonta to a full approval have taken a knock.
Open in Who Shared Issue with article?
See all 11,215 licensed articles (11,227 Total)